Electromed (ELMD) is a profitable medical device company in a small but growing market niche. The company has historically experienced uneven bottom line growth as it is dependent on one-time sales of its main product. Activist funds have taken large positions believing the stock to be undervalued. Management has restructured its sales team as it attempts to gain market penetration. The restructuring will provide immediate cost savings and potentially improve the company's earnings. The company is also an attractive acquisition target as it has been consistently profitable and cash flow positive.
Strategy
ELMD,